
Conference Coverage
about 21 hours ago
Real-World Data Support Cemiplimab Efficacy in Advanced NSCLCabout 23 hours ago
Precision Medicine Equity Hinges on Systems, but Coverage Gaps LingerLatest Content

Shorts










Center on Health Equity & Access
All News

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

San Francisco experts say payer step edits and weak biologic follow-up slow atopic dermatitis care and point to pharmacy teams and dashboards.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."

The updated label now includes phase 3 data comparing aficamten monotherapy with metoprolol in adults with symptomatic obstructive HCM.

Panelists concurred that precision medicine can serve to exacerbate care inequality if not everyone can access these therapeutics.

IL-23 inhibitors linked to lower psoriatic arthritis risk than JAK inhibitors, and IL-17 inhibitors showed higher risk.

Once weekly tirzepatide significantly reduces body mass index in adolescents with obesity compared with placebo.
































